In 2015, Mylan pharmaceuticals received final approval from the Food and Drug Administration for its Supplemental Abbreviated New Drug Application and introduced three new intermediate strengths of transdermal fentanyl patches to the U.S. drug market.1 With this approval, Mylan added 37.5 , 62.5, and 87.5 mcg/hr strength patches to existing 12, 25, 50, 75, and 100 mcg/hr strength patches. Today, these intermediate strength patches cost many times more than older strengths. In this commentary, we discuss the clinical implications of intermediate strengths of the fentanyl patch, explore mechanisms for price differences, and offer practice-based and policy solutions to address these differences.
Get full access to this article
View all access options for this article.
References
1.
van den Beuken-van EverdingenMH, HochstenbachLM, JoostenEA, et al.Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage, 2016; 51(6):1070.e9–1090.e9; doi: 10.1016/j.jpainsymman.2015.12.340. Epub 2016 Apr 23.
2.
DueñasM, OjedaB, SalazarA, et al. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res, 2016; 9:457–467. Published 2016 Jun 28; 9: 10.2147/JPR.S105892.
3.
BlinderVS. Pain, Financial hardship, and employment in cancer survivors. J Clin Oncol, 2022; 40(1):1–4; doi: 10.1200/JCO.21.01812. Epub 2021 Nov 18.
4.
GoodRx Holdings Inc: S-1 Registration Statement. US Securities and Exchange Commission: Washington, DC; 2020.
5.
GuptaA, NshutiLS, GrewalUS, et al.Financial burden of drugs prescribed for cancer-associated symptoms. JCO Oncol Pract, 2021;OP2100466; doi: 10.1200/OP.21.00466.
6.
PatelMS, DaySC, HalpernSD, et al. Generic medication prescription rates after health system-wide redesign of default options within the electronic health record. JAMA Intern Med, 2016; 176(6):847–848; doi: 10.1001/jamainternmed.2016.1691. PMID: 27159011; 176(6): PMC7240800.
7.
SocalMP, BaiG, CordeiroT, et al.Association between waste-free formularies and prescription drug spending among self-insured employers. JAMA Netw Open, 2021; 4(10):e2131486; doi: 10.1001/jamanetworkopen.2021.31486. PMID: 34709391.
